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Magnesium supplementation has been reported to prevent cardiovascular diseases through the decrease of plasma lipids and to improve
endothelial function in patients with coronary artery disease. In the present work, we evaluated whether high magnesium concentrations can
directly affect the function of cultured endothelial cells, which play a crucial role in maintaining the functional integrity of the vascular wall.
We cultured human umbilical vein endothelial cells for various times in media containing different concentration of magnesium (range 2 to
10 mM) and compared them to the corresponding controls (1 mM Mg). High Mg concentrations stimulated endothelial proliferation,
enhanced the motogenic response to angiogenic factors and attenuated the response to lipopolysaccharide (LPS). In addition, we demonstrate
that high concentrations of magnesium did not modulate the levels of plasminogen activator inhibitor-1, but enhanced the synthesis of nitric
oxide, in part through the up-regulation of endothelial nitric oxide synthase.
Our results demonstrate a direct role of magnesium in maintaining endothelial function. We therefore anticipate that magnesium may have a
protective effect against atherosclerosis and could play a role in promoting the growth of collateral vessels in chronic ischemia. Moreover,
because it induces the synthesis of nitric oxide, this cation could be a helpful tool in hypertension as well as in preventing thrombosis.
D 2004 Elsevier B.V. All rights reserved.Keywords: Endothelial cell; Magnesium; Atherosclerosis; Nitric oxide1. Introduction
Magnesium, the most abundant intracellular divalent
cation, plays an essential role in a wide range of fundamen-
tal cellular reactions [1]. Since it functions as allosteric
modulator of several enzymes or it bridges structurally
distinct molecules, magnesium (Mg) coordinates DNA
duplication with an adequate metabolic response. Indeed,
the cation stabilizes DNA, promotes DNA replication and
transcription, influences RNA translation, induces ribosome
assembly and regulates the opening-closure of ion channels
[2]. On these bases, it is not surprising that many symptoms
and diseases are attributed to altered Mg homeostasis.
Evidence has been accumulating showing that magnesium0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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stress response and decreases specific immune response
[3,4]. Low magnesium status is also important in the
pathogenesis of cardiovascular diseases [5] and has a role
in hypertension [6] and thrombosis [7]. All these clinical
situations recognize an endothelial dysfunction as a com-
mon pathogenic event [8].
The beneficial effects of both oral and intravenous Mg
have been shown. Mg fortification of drinking water suc-
ceeded in the inhibition of atherogenesis in APO-E-deficient
mice fed with a high cholesterol diet [9]. Oral Mg therapy
has been associated with significant improvement of endo-
thelial function in patients with coronary artery disease [10]
and with a decrease of plasma concentrations of triglycer-
ides, VLDL and apo-B [11]. Since an inverse correlation
between dietary Mg intake and blood pressure exists, it is
noteworthy that Mg supplementation prevents the develop-
ment and severity of hypertension [12]. In addition, intra-
venous magnesium (Mg) is a promising agent in the
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the ischemic myocardium, but also as an anti thrombotic
drug [13]. Accordingly, intravenous Mg infusion is able to
reduce infarct size by about 50% in model where both
reperfusion injury and thrombosis occur [14]. Moreover,
intravenous magnesium sulfate has been shown to prevent
eclampsia by reducing cerebral vasoconstriction and ische-
mia [15] and seems also to be neuroprotective in patients
within 12 h of acute stroke [16].
We have recently demonstrated that low Mg promotes
endothelial dysfunction that might play a role in atherogen-
esis and thrombogenesis [17]. Since experimental and clin-
ical studies suggest that oral or injected Mg, which increases
the plasma levels of the cation, prevents or retards diseases in
which the endothelium is involved, we investigated the
effects of high concentrations of Mg on human endothelial
cells with a particular attention to those functional compo-
nents that are important in angiogenesis, atherogenesis and
thrombogenesis.Fig. 1. Stimulation of HUVEC proliferation by high magnesium. HUVEC
were cultured for different times in media containing 1.0, 2.0, 5.0, 10.0 mM
Mg. After 3 days, the cells were harvested by digestion with trypsin and
viable cells counted using a Burker chamber. The figure shows a
representative experiment in triplicate (out of seven performed).2. Materials and methods
2.1. Endothelial cell culture, proliferation and migration
HUVEC-C were obtained from the American Type
Culture Collection (ATCC) and cultured in M199 contain-
ing 10% fetal calf serum, Endothelial Cell Growth supple-
ment ECGS (150 Ag/ml) and heparin (5 U/ml) on 2%
gelatin-coated dishes. The cells were routinely evaluated
for the expression of endothelial markers, i.e. endothelial
nitric oxide synthase, VE-cadherin and CD34. All culture
reagents were from Gibco. In all the experiments the cells
were seeded in growth medium; after 24 h, the medium
was changed to expose the cells to various concentrations
of Mg. In all the experiments, MgSO4 was utilized to
increase the concentration of the cation in the culture
media. No significant difference was observed when we
used MgSO4 or MgCl2 to increase Mg concentrations in
our culture media.
Proliferation assays were performed on cells seeded at low
density (7500/cm2) cultured in growth medium containing
different concentrations ofMg for 3 days. The cells were then
trypsinized, stained with trypan blue solution (0.4%) and the
viable cells were counted using a Burker chamber. The
experiments have been repeated several times, always in
triplicate.
Migration of cells cultured in the presence of different
concentrations of Mg for 3 days was determined using an in
vitro model of wound repair as previously described [18].
Briefly, confluent endothelial cells were wounded and treated
with 20 ng/ml of Hepatocyte Growth Factor (HGF), Fibro-
blast Growth Factor (FGF) or Vascular Endothelial Growth
Factor (VEGF) for 18 h. The number of cells migrating from
the wound origin was counted with a light microscope at
100 magnification using a grid. The values represent themeanF standard deviation of five fields, each condition
tested in triplicate.
2.2. Adhesion assay
The monocytoid cell line U937 was used in these
studies as previously described [19]. The cells were
cultured in RPMI medium containing 10% FCS. Conflu-
ent endothelial cells were cultured in 24-well plates in
medium containing different concentrations of Mg for 3
days and exposed to LPS for 4 h. At the end of the
incubation, the wells were rinsed three times and 2 105
U937 cells were added to each well. After 1 h, the
nonadherent U937 cells were rinsed off and the wells
were fixed with 1% glutaraldehyde. The number of
attached U937 cells was counted in twenty microscopic
fields defined by an eyepiece. The experiments were
performed at least three times in triplicate [19].
It is possible that Mg binds LPS, which is negatively
charged, thus impairing its activity. To rule out this possi-
bility, we incubated LPS (5 Ag/ml) with MgSO4 (20 mM)
for 16 h to allow the interaction. We then added the mixture
to confluent HUVEC cultured under basal conditions, i.e. in
1.0 mM Mg, for 4 h. We could not detect any major
difference in the induction of endothelial adhesiveness by
LPS alone or LPS incubated with MgSO4.
2.3. Western blot analysis
HUVEC were lysed in 10 mM Tris–HCl (pH 7.4)
containing 3 mM MgCl2, 10 mM NaCl, 0,1% SDS, 0,1%
Triton X-100, 0,5 mM EDTA and protein inhibitors,
separated on 10% SDS-PAGE and transferred to nitrocel-
lulose sheets. Western blot was performed using antibodies
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thelial nitric oxide synthase (NOS) (Tebu-bio). Secondary
antibodies were labeled with horseradish peroxidase
(Amersham Pharmacia Biotech). The SuperSignal chemi-
luminescence kit (Pierce) was used to detect immunoreac-
tive proteins according to the manufacturer’s instruction.
Western blots have been repeated three times on cell
extracts from different experiments.Fig. 2. Stimulation of HUVEC migration by high magnesium. (A) Confluent HUV
days, the cells were wounded and treated with HGF (20 ng/ml) for 18 h. The n
microscope at 100X magnification using a grid. The values represent the meanF
figure shows a representative experiment (out of five performed). (B) Confluent
cells were wounded and treated with FGF or VEGF (20 ng/ml) for 18 h. The num
values represent the meanF standard deviation of five fields, each condition test
performed).2.4. NOS activity
NOS activity was measured by monitoring the conversion
of 3H-arginine to 3H-citrulline. The assay was performed on
40 Ag of cell extracts. Briefly, cell extracts were incubated in a
reaction buffer (10 mM NADPH, 1 ACi/Al 3H-arginine, 25
mM Tris–HCl, 3 AM BH4, 1 AM FAD, 1 AM FMN, 100 nM
CaM, and 60 AM CaCl2) for 1 h at room temperature. The
physica Acta 1689 (2004) 6–12EC were cultured in media containing 1.0, 2.0, 5.0, 10.0 mM Mg. After 3
umber of cells migrating from the wound origin was counted with a light
standard deviation of five fields, each condition tested in triplicate. The
HUVEC were cultured in media containing 5.0 mM Mg. After 3 days, the
ber of cells migrating from the wound origin was counted as described. The
ed in triplicate. The figure shows a representative experiment (out of three
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HEPES pH 5.5, 5 mM EDTA). One hundred microliters of
pre-equilibrated resin (DOWEX 50WX8 200–400 mesh, H
form, Sigma) was added to each sample, shaken and centri-
fuged. The flow-through was collected and the radioactivity
was quantified in a scintillation counter.Fig. 4. PAI-1 expression in HUVEC cultured in high magnesium. Western
blot was performed on HUVEC cultured in different concentrations of Mg
(1.0, 2.0, 5.0 and 10.0 mM Mg) for 3 days as described in Section 2.3. Results
3.1. Modulation of endothelial proliferation and migration
by increased concentrations of extracellular Mg
HUVEC were grown in the presence of different con-
centrations of extracellular Mg for various times. Physio-
logic circulating Mg levels are approximately 1.0 mM. Mg
(2 mM) is a concentration that falls within the physiolog-
ical/pathophysiological range, whereas 5 and 10 mM are
very high concentrations previously utilized in in vitro
studies [20,21]. On the other hand, it is possible that such
concentrations are locally reached after Mg intravenous
injection. In human aortic endothelial cells, extracellular
Mg is reported to rapidly increase intracellular ionized Mg
[22].
We observed a dose-dependent reproducible stimulation
of cell proliferation in response to increased concentrations
of Mg (Fig. 1). This effect was reversible within 48 h (not
shown).
High Mg also potentiates HUVEC migration in response
to angiogenic factors. We cultured the cells for 3 days in
medium containing 1.0, 2.0, 5.0 and 10.0 mM Mg and then
we added HGF (20 ng/ml) for 18 h. As shown in Fig. 2A,
high Mg renders the cells more sensitive to the mitogenic
action of HGF. Similar results were obtained when HUVECFig. 3. Induction of HUVEC/U937 interactions by high magnesium. Confluent HU
or not to LPS (0.5 Ag/ml). After 4 h, U937 cells were added. One hour later, the no
was counted in 20 microscopic fields defined by an eyepiece. The figure showswere cultured in 5.0 mM Mg for 3 days before adding FGF
or VEGF (20 ng/ml) for 18 additional hours (Fig. 2B).
3.2. Modulation of endothelial adhesiveness and thrombotic
properties by increased concentrations of extracellular Mg
We evaluated the interaction of the monocytoid U937
cells to HUVEC cultured in medium containing 1.0, 2.0, 5.0
and 10.0 mM Mg for 3 days and found a decrease in
endothelial-U937 cell interactions (Fig. 3). Bacterial lipo-
polysaccharide (LPS) is a potent inducer of endothelial
adhesiveness. When cultured in high concentrations of Mg
for 3 days, endothelial response to LPS (0.5 Ag/ml) is
markedly reduced in a dose-dependent fashion (Fig. 3).
One of endothelial functions is the maintenance of non
thrombogenic blood–tissue interface [8]. We evaluated the
expression of plasminogen activator inhibitor (PAI)-1,
which is pro-thrombotic. We did not detect any major
modulation of PAI-1 (Mr 50 kDa) in HUVEC grown for 3VEC were cultured in 1.0, 2.0, 5.0 and 10.0 mMMg for 3 days and exposed
nadherent U937 cells were rinsed off and the number of attached U937 cells
a representative experiment in triplicate (out of four performed).
Fig. 5. NOS in HUVEC grown in high magnesium. (A) The activity of
NOS in HUVEC cultured for 3 days in high Mg was measured as described
on 40 Ag of extracts obtained from HUVEC cultured in 1.0 or 5.0 mM Mg.
(B) Western blot was performed on HUVEC cultured in 1.0 or 5.0 mM Mg
for 3 days as described in Section 2.
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detected by Western blot analysis (Fig. 4). Only at very high
concentrations of Mg (10 mM) a slight, albeit reproducible
decrease of the total amount of PAI-1 was evident. Another
molecule known to be implicated in preventing thrombosis
is nitric oxide (NO) because of its anti-platelets actions. We
therefore measured the synthesis of NO in HUVEC cultured
for 3 days in 1.0 and 5.0 mM Mg. Fig. 5A shows that high
Mg stimulates the synthesis of NO. This is in part due to an
increase in the total amount of eNOS in HUVEC cultured
for 3 days in medium containing 5 mM Mg, as determined
by Western blot (Fig. 5B).4. Discussion
Endothelial cells cover the entire inner surface of the
blood vessels and play a crucial role in maintaining the
functional integrity of the vascular wall. The endothelium
actively controls haemostasis (exerting control on platelets,
coagulation and fibrinolytic systems), vascular tone, endo-
thelial permeability and medial smooth muscle cell growth
[8]. Endothelial dysfunctions play an important pathogenic
role in several diseases, among which atherosclerosis,
hypertension and thrombosis [8]. In addition, endothelial
cells are protagonists in angiogenesis, i.e. the branching and
sprouting of capillaries from pre-existing blood vessels,
which is a tightly controlled event crucial in development,
in reproduction and wound healing [8]. Because of theirstrategical location at the interface between blood and
vessels, endothelial cells are readily exposed to various
signals such as cytokines, metabolites, ions, free radicals,
some of which may promote maladaptative functional
changes. Among others, abnormal magnesium (Mg) status
has been reported to be important in the pathogenesis of
cardiovascular diseases. Interestingly, hypomagnesemia,
which is very frequent in western countries, is a common
denominator in hypertension [6], atherosclerosis [23] and
thrombosis [7]. The demonstration that low concentrations
of Mg promote endothelial dysfunctions may explain some
pathogenic aspects of these diseases [17].
Mg supplementation, which increases the plasma levels
of the cation, is reported to be beneficial in coronary artery
disease, hypertension and thrombosis. We therefore evalu-
ated the effects of high concentrations of Mg on cultured
endothelial cells.
We found that high Mg stimulates the proliferation of
HUVEC. This is in agreement with previous studies report-
ing an increase in the growth bovine capillary endothelial
cells [20]. Indeed, it is well accepted that Mg is necessary
for cell cycle progression in different cell types [2]. Recent-
ly, we have shown that low extracellular Mg concentrations
inhibit endothelial growth and this correlates with a marked
down-regulation of CDC25B, a phosphatase which controls
the transition from the G2 to the M phase of the cell cycle
[17]. The inhibition of cell proliferation is probably also
depending on Mg deprivation-induced metabolic adapta-
tions, such as a decrease in high energy phosphates and a
decline in protein and carbohydrate synthesis. It is therefore
conceivable that the stimulation of endothelial growth by
high Mg is partially mediated by the regulation of energy
production and the stimulation of the activity of enzymes
which require Mg [2]. These metabolic events may also play
a role in the enhancement of endothelial migration observed
in endothelial cells cultured in high Mg. Interestingly, high
Mg potentiates the response of HUVEC to motogenic
factors. Since Mg is a cofactor of adenylate cyclase and
cAMP-dependent phosphodiesterase, we speculate that the
sensitization to the motogenic factors might be dependent
on the fact that elevated Mg levels could alter cAMP, which
modulates endothelial migration [24]. Moreover, it is note-
worthy that Mg is required for the assembly of actin
polymers and for myosin ATPase activity, two key compo-
nents of the motor responsible for cell migration [1]. The
fact that Mg up-regulates integrin function [25] could
provide another possible explanation to the enhancement
of endothelial migration. Recently, it has been shown that
Mg serves as a chemotactic factor for HUVEC probably
through a receptor-mediated mechanisms eventually involv-
ing a novel member of the cation sensing receptors [26].
The effects of Mg on endothelial cell migration and
proliferation may have pathophysiologic significance. Giv-
en our results, it is possible that high Mg facilitates the re-
endothelialization of vascular injuries, thus preventing ex-
cessive subintimal proliferation of smooth muscle cells and
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insights into the role of Mg in angiogenesis. It is known
that, within wounding, Mg is elevated [27]. In such a
favourable microenvironment, endothelial cells are induced
to migrate and grow, thus accelerating the formation of new
vessels.
One of the earliest events in atherogenesis is the adhesion
of monocytes to the endothelium [28]. While low Mg
stimulates monocyte–endothelial interactions through the
up-regulation of VCAM [9], we here show that high Mg
inhibits this phenomenon. Moreover, high Mg desensitizes
the cells to the detrimental effects of LPS. These data could
explain the protective effect of Mg against atherosclerosis
described both in humans and in experimental models as
well as in septic shock [29].
Experimental studies have demonstrated that Mg is also
capable of preventing thrombosis. The prothrombotic ef-
fect of low Mg is due, at least in part, to the up-regulation
of PAI-1, which is increased in a variety of clinical
conditions such as coronary artery disease and venous
thrombosis [30]. We could not detect any modulation in
the levels of PAI-1 in HUVEC exposed to high concen-
trations of Mg, while we found an increased synthesis of
nitric oxide. Over the last 15 years, endothelial NO has
been shown to limit platelet activation, adhesion and
aggregation [31] and, to this purpose, it is noteworthy that
Mg inhibits acute platelet-dependent stent thrombosis in
swine [32]. NO was originally discovered as a vasodilator
product of endothelium [31]. Indeed, NO acts in a para-
crine fashion to stimulate smooth muscle cells guanylyl
cyclase to produce 3V,5V-cyclic monophosphate which
causes relaxation of the blood vessels [33]. The fact that
Mg stimulates NO synthesis may explain also the useful-
ness of the cation in preventing development and severity
of hypertension [12]. Apart from regulating platelet func-
tion and arterial pressure, NO also contributes to the
angiogenic program by triggering endothelial cell growth
and differentiation [34]. Interestingly, elevation of NOS
activity in correlation with angiogenesis and tumor growth
and aggressiveness has been extensively reported in ex-
perimental and human tumors [34].
Given our data, it is intriguing to speculate on the
possible salutary role of increasing plasma levels of Mg
to facilitate the healing of vascular injuries, to prevent
atherosclerosis, hypertension and coronary spasm and in
inducing coronary collateral growth in chronic myocardial
ischemia. On the other hand, caution should be suggested in
neoplastic patients, since an increase in angiogenesis could
lead to a rapid growth and, eventually, metastatization of
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